Business Schmidt retires, Cronos welcomes back Gorenstein as CEO The firm's fortunes continued to dwindle under the CPG expert's leadership Nick LabaMarch 21, 2022
Business Cronos reports US$134M Q4 net loss on closing of Peace Naturals facility The firm's annual losses reached US$396.1 million Nick LabaMarch 1, 2022
Business Cronos releases delayed Q3 results, adds US$236.1M impairment charge Company stock hit a 4-year low on Friday Nick LabaFebruary 18, 2022
Business Cronos continues to tumble after receiving Nasdaq delinquency letter The letter has no current impact on its listing, company says Nick LabaNovember 23, 2021
News Cronos continues cash burn with US$161M loss in Q1 With revenue of just US$12.6M in Q1, the Canadian pot firm says it's finally ready to commercialize its synthetic cannabinoids joint venture Jared GnamMay 7, 2021
Industry update Organigram shares surge on big tobacco deal British American Tobacco to invest $221M in the Canadian producer to develop new innovative weed and CBD products Jared GnamMarch 11, 2021
Industry update Cronos stock drops on US$111.7M Q4 loss Despite continued cash burn, the Canadian pot firm remains bullish on its Kristen Bell-partnered US CBD brand Happy Dance Jared GnamFebruary 26, 2021
Industry update Cronos stock pops despite rising losses While third quarter revenues climbed 15% sequentially, the Ontario producer continues to pile up operating losses Jared GnamNovember 5, 2020
Analysis Croptober 2020: Why a tsunami of Canadian outdoor will go up in smoke Supply gluts, collapsing wholesale prices and Canadian regulations put an incoming 360,000 kgs of outdoor weed at risk of going unsold Jared GnamOctober 20, 2020
The weed wire Amyris scales production of its first yeast-created cannabinoid Cannabigerol (CBG) shows higher efficacy in one-third of current CBD topical applications, company says Nick LabaSeptember 1, 2020